NCT00883090View on ClinicalTrials.gov

A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Factor XIII Deficiency
Interventions
BIOLOGICAL

FXIII Concentrate (Human)

Subjects will receive approximately 40 U/kg of FXIII every 28 days for 3 doses administered as a bolus intravenous (IV) injection at approximately 250 U/minute.

Trial Locations (6)

36305

Study Site, Dothan

92868

Study Site, Orange

94115

Study Site, San Francisco

95204

Study Site, Stockton

02115

Study Site, Boston

Unknown

Study Site, Santa Cruz de Tenerife

Sponsors

Lead Sponsor

CSL Behring
All Listed Sponsors
lead

CSL Behring

INDUSTRY